Abstract:Abstract Objective Maternally inherited diabetes and deafness (MIDD) is characterized by progressive insulin secretory disorder caused by impairment of mitochondrial adenosine triphosphate (ATP) production in pancreatic beta-cells. The amino acid 5-aminolevulinic acid (5-ALA) is the first heme biosynthetic precursor and the administration of 5-ALA combined with sodium ferrous citrate (SFC) enhance heme production, leading to improvement of mitochondrial function and ATP production. Several studies showed that the treatment with 5-ALA/SFC improved glycemic tolerance in both patients with prediabetes and those with type 2 diabetes. However, no previous studies investigated the efficacy of 5-ALA in patients with MIDD. We carried out the pilot trial to investigate whether the administration of 5-ALA/SFC can improve insulin secretion and glucose tolerance in patients with MIDD. Methods We enrolled five patients with MIDD receiving multiple daily injections of insulin. The patients were administered 5-ALA/SFC 100 mg twice a day (200 mg per day) for 24 weeks as adjunctive to insulin treatment. The patients underwent a 75-g oral glucose tolerance test (OGTT) twice before (1 st -OGTT) and 24 weeks after the initiation of 5-ALA/SFC (2 nd -OGTT). We measured levels of plasma glucose, insulin, and glucagon at fasting (0 min), and 30, 60 and 120 min after glucose load (Study protocol: Nakamura Y et al. Medicine (Baltimore). 2021; 100: e25100). Results The mean levels of HbA1c tended to decrease from 8.3% to 7.9% (p = 0.36) even though total insulin doses had not changed during the 24 weeks of 5-ALA/SFC administration. In the 2nd -OGTT comparing to the 1 st -OGTT, four of the five patients showed a tendency of improvement in glucose levels with a certain degree of insulin increase, but one patient did not show any improvement. The means of area under the curve (AUC) of serum insulin from fasting to 120 min during 2nd -OGTT was 30% larger but not significant compared to that during 1st -OGTT (p = 0. 077). The late phase of glucose excursion during OGTT determined by AUC of plasma glucose from 60 to120 min during 2nd -OGTT showed 10% reduction compared to that during 1st -OGTT (p = 0. 041). The glucagon levels during OGTT were comparable between before and after 5-ALA/SFC administration. The indexes of insulin sensitivity calculated by the homeostasis model assessment of insulin resistance or Matsuda index were not significantly changed between before and after 5-ALA/SFC administration. None of the patients experienced any adverse events during the study. Conclusions The administration of 5-ALA/SFC as adjunctive to insulin therapy might be a novel effective treatment for MIDD that improves insulin secretion via amelioration of mitochondrial function. Presentation: No date and time listed

5-Aminolevulinic acid bypasses mitochondrial complex I deficiency and corrects physiological dysfunctions in Drosophila

Expression of alternative oxidase in Drosophila ameliorates diverse phenotypes due to cytochrome oxidase deficiency

5‐Aminolevulinic acid and sodium ferrous citrate ameliorate muscle aging and extend healthspan in Drosophila

MPS 07-06 5-AMINOLEVULINIC ACID, A MATERIAL FOR MITOCHONDRIAL ELECTRON CARRIER, IMPROVES EXERCISE ENDURANCE THROUGH BOTH MUSCLE ENHANCEMENT AND ACTIVATION OF MUSCLE MITOCHONDRIA IN SARCOPENIC MICE.

5-Aminolevulinic Acid with Sodium Ferrous Citrate Induces Autophagy and Protects Cardiomyocytes from Hypoxia-Induced Cellular Injury Through MAPK-Nrf-2-HO-1 Signaling Cascade.

Dichloroacetate and thiamine improve survival and mitochondrial stress in a C. elegans model of dihydrolipoamide dehydrogenase deficiency

5-aminolevulinic acid combined with sodium ferrous citrate ameliorates H2O2-induced cardiomyocyte hypertrophy via activation of the MAPK/Nrf2/HO-1 pathway.

5-Aminolevulinic Acid Combined with Sodium Ferrous Citrate Ameliorates H2O2-induced Cardiomyocyte Hypertrophy Via Activation of the MAPK/Nrf2/HO-1 Pathway

Cell-permeable succinate prodrugs bypass mitochondrial complex I deficiency

5-ALA Ameliorates Hepatic Steatosis Through AMPK Signaling Pathway

Effect of 5-aminolevulinic acid on erythropoiesis: a preclinical in vitro characterization for the treatment of congenital sideroblastic anemia

Pharmacological inhibition of ALCAT1 mitigates amyotrophic lateral sclerosis by attenuating SOD1 protein aggregation

Augmenter of Liver Regeneration Regulates Cellular Iron Homeostasis by Modulating Mitochondrial Transport of ATP-Binding Cassette B8

The Chronic Effects Of 5-Aminolevulinic Acid Plus Sodium Ferrous Citrate On Pre-Diabetic Wistar Rats

Alternative oxidase‐mediated respiration prevents lethal mitochondrial cardiomyopathy

The complex I subunit NDUFA10 selectively rescues Drosophila pink1 mutants through a mechanism independent of mitophagy

Complex I Deficiency in M.3243a>g Fibroblasts is Alleviated by Reducing NADH Accumulation

Pro-oxidant effect of ALA is implicated in mitochondrial dysfunction of HepG2 cells

Combinatorial glucose, nicotinic acid and N-acetylcysteine therapy has synergistic effect in preclinical C. elegans and zebrafish models of mitochondrial complex I disease

Mitochondrial energetics is impaired in very long-chain acyl-CoA dehydrogenase deficiency and can be rescued by treatment with mitochondria-targeted electron scavengers

ODP158 A Pilot Trial on the Efficacy of 5-Aminolevulinic Acid on Glucose Tolerance in Patients with Maternally Inherited Diabetes and Deafness